Katharina Kolbe1, Ivonne Haffner2, Katrin Schierle3, Dieter Maier4, Birgitta Geier4, Birgit Luber5, Hendrik Bläker6, Christian Wittekind6, Florian Lordick1. 1. Department of Oncology, Gastroenterology, Hepatology, Pulmonology and Infectious Disease, Leipzig University Medical Center, University Cancer Center Leipzig (UCCL), Leipzig, Germany. 2. Department of Oncology, Gastroenterology, Hepatology, Pulmonology and Infectious Disease, Leipzig University Medical Center, University Cancer Center Leipzig (UCCL), Leipzig, Germany. ivonne.haffner@medizin.uni-leipzig.de. 3. Institute of Pathology, Heilbronn SLK-Kliniken GmbH, Heilbronn, Germany. 4. Biomax Informatics AG, 82152, Planegg, Germany. 5. Institute of Pathology, Technische Universität München, Munich, Germany. 6. Department of Pathology, Leipzig University Medical Center, Leipzig, Germany.
Abstract
PURPOSE: The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90 (22.3%) of 404 cases (central versus local testing) and were associated with negative impact on survival for trastuzumab-treated patients. Here, we investigated methodological and biological variables that may promote deviating HER2 test results. METHODS: We analyzed HER2 testing procedures and participation in quality assurance programs of 105 participating local pathology laboratories. Furthermore, tumor localization and histological subtypes were compared between patients with centrally confirmed (central HER2 + /local HER2 + , n = 68) and unconfirmed HER2 status (central HER2 -/local HER2 + , n = 68). RESULTS: For central HER2 testing, concordance between in situ hybridization (ISH) and immunohistochemistry (IHC) was 98.3%, with IHC sensitivity of 93.3% (84 IHC + of 90 ISH +), specificity of 99.5% (389 IHC- of 391 ISH-), and a positive diagnosis rate of 97.7%. Central confirmation of the local HER2 IHC scores were seen for the majority of locally HER2- IHC 0/1 (172/178; 96.6%), but less frequently for locally IHC3 + (57/124; 46.0%) cases. Deviation rate was not associated with IHC antibody platform used in the local pathology institute neither with participation in quality-assuring tests. Regarding tumor characteristics, deviating test results were more frequently found in GC vs. EGJC (69.1% vs. 39.7%; p = 0.001) and in Laurén diffuse vs. intestinal subtype (23.5% vs. 5.9%, p = 0.004). CONCLUSION: Tumor localization and histological subtype have an impact on HER2 test deviation rates. Assessment of HER2 remains challenging for GC and EGJC.
PURPOSE: The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90 (22.3%) of 404 cases (central versus local testing) and were associated with negative impact on survival for trastuzumab-treated patients. Here, we investigated methodological and biological variables that may promote deviating HER2 test results. METHODS: We analyzed HER2 testing procedures and participation in quality assurance programs of 105 participating local pathology laboratories. Furthermore, tumor localization and histological subtypes were compared between patients with centrally confirmed (central HER2 + /local HER2 + , n = 68) and unconfirmed HER2 status (central HER2 -/local HER2 + , n = 68). RESULTS: For central HER2 testing, concordance between in situ hybridization (ISH) and immunohistochemistry (IHC) was 98.3%, with IHC sensitivity of 93.3% (84 IHC + of 90 ISH +), specificity of 99.5% (389 IHC- of 391 ISH-), and a positive diagnosis rate of 97.7%. Central confirmation of the local HER2 IHC scores were seen for the majority of locally HER2- IHC 0/1 (172/178; 96.6%), but less frequently for locally IHC3 + (57/124; 46.0%) cases. Deviation rate was not associated with IHC antibody platform used in the local pathology institute neither with participation in quality-assuring tests. Regarding tumor characteristics, deviating test results were more frequently found in GC vs. EGJC (69.1% vs. 39.7%; p = 0.001) and in Laurén diffuse vs. intestinal subtype (23.5% vs. 5.9%, p = 0.004). CONCLUSION: Tumor localization and histological subtype have an impact on HER2 test deviation rates. Assessment of HER2 remains challenging for GC and EGJC.
Authors: Y J Bang; G Giaccone; S A Im; D Y Oh; T M Bauer; J L Nordstrom; H Li; G R Chichili; P A Moore; S Hong; S J Stewart; J E Baughman; R J Lechleider; H A Burris Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Sofia Asioli; Francesca Maletta; Ludovica Verdun di Cantogno; Maria A Satolli; Marina Schena; Carla Pecchioni; Cristina Botta; Luigi Chiusa; Luca Molinaro; Luca Conti; Giuseppe Viale; Giuseppe Ingravallo; Eugenio Maiorano; Anna Sapino Journal: Hum Pathol Date: 2012-06-01 Impact factor: 3.466
Authors: C Bozzetti; F V Negri; C A Lagrasta; P Crafa; C Bassano; I Tamagnini; G Gardini; R Nizzoli; F Leonardi; D Gasparro; R Camisa; S Cavalli; S Capelli; E M Silini; A Ardizzoni Journal: Br J Cancer Date: 2011-04-12 Impact factor: 7.640
Authors: J D Barros-Silva; D Leitão; L Afonso; J Vieira; M Dinis-Ribeiro; M Fragoso; M J Bento; L Santos; P Ferreira; S Rêgo; C Brandão; F Carneiro; C Lopes; F Schmitt; M R Teixeira Journal: Br J Cancer Date: 2009-01-20 Impact factor: 7.640